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A B S T R A C T
The aim of the study was to assess the correlation between the levels of catecholamines and cerebral hemodynamics in
patients with chronic post-traumatic stress disorder (PTSD). The study included 50 patients with chronic PTSD hospi-
talized for psychiatric treatment for the first time, and 50 healthy control subjects. All study subjects were in the 30–50
age group. In PTSD group, determination of vanllylmandelic acid (VMA), an epinephrine and norepinephrine metabo-
lite, in 24-h urine and transcranial Doppler (TCD) sonography of the circle of Willis vasculature were performed on the
first day of hospital stay. The same diagnostic procedures were repeated upon the completion of 21-day medicamentous
psychiatric treatment. Initial analysis revealed concurrently elevated 24-h VMA in 29 (58.00%) patients and increased
values of the mean blood flow velocity (MBFV) in the circle of Willis vasculature in 34 (68.00%) patients, indicating a
high correlation of the respective parameters (p=0.3290). Second analysis performed after 21-day psychiatric treatment
showed concurrently elevated 24-h VMA in eight (16.00%) patients and increased MBFV in the circle of Willis vas-
culature in nine (18.00%) patients, also pointing to a high correlation of the parameters observed (p=0.7906). In the con-
trol group, only two (4.00%) subjects had elevated MBFV in the circle of Willis vessels, whereas the level of 24-h VMAwas
normal in all control subjects. Study results pointed to a significant association between elevated levels of stress hor-
mones and increased MBFV in the circle of Willis vasculature caused by cerebral vasospasm. Medicamentous psychiatric
treatment for PTSD administered for three weeks significantly reduced the proportion of PTSD patients with elevated
levels of the catecholamine metabolite and cerebral vasospasm. Study results showed a high correlation between diurnal
VMA level and elevated MBFV in the circle of Willis vessels, clearly demonstrating the effect of prolonged elevation of
catecholamine levels on cerebral hemodynamics.
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Introduction
Behavioral changes in war veterans were recognized
as early as the 19th century; however, studies of post-
-traumatic stress disorder (PTSD) were only initiated af-
ter World War II1–3. Considering the ever increasing rate
of traumatic events in today’s world (wars, terrorist at-
tacks, disasters, traffic and rail accidents, marine and air
disasters, murder, rape, etc.), which are associated with
strong traumatic stressor, PTSD is emerging as a major
public health problem4,5. The clinical picture of chronic
PTSD with mental disturbances and physical manifesta-
tions of stress is well known. The manifestations of in-
creased sympathetic activity in patients with chronic
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PTSD include accelerated pulse rate, elevated blood pre-
ssure and hyperventilation6–8. Increased levels of vanllyl-
mandelic acid (VMA) as an end-product of catecholamine
metabolism have been demonstrated in patients with
chronic PTSD9,10. Changes on transcranial Doppler (TCD)
sonography in terms of the mean blood flow velocity
(MBFV) increase in the circle of Willis vasculature have
been described, with the characteristics of frequency
spectra and parameters of spectral frequency analysis in-
dicating cerebral vasospasm11–13. Cerebral vasospasm is a
result of prolonged contraction of cerebral artery wall
smooth muscle cells14–18.
As other risk factors for cerebrovascular disease such
as arterial hypertension, cigarette smoking, alcoholism,
hyperlipidemia and diabetes mellitus also show a greater
prevalence in chronic PTSD patients, there is a high risk
of a precipitated atherosclerotic process and develop-
ment of cardiovascular disorders19–25. These issues pose
the need of additional studies and long-term follow up of
patients with chronic PTSD.
The aim of the present study was to assess the possi-
ble association between catecholamine levels and these
specific changes of cerebral hemodynamics in chronic
PTSD patients, and to monitor the effect of psychiatric
treatment on these parameters.
Patients and Methods
The study included 50 Croatian Army soldiers aged
30–50, actively engaged in the 1991–1995 war. None of
the study patients had a pre-war history of mental or so-
matic disorders. The diagnosis of PTSD was made by a
psychiatrist according to DSM-IV and ICD-10 diagnostic
criteria26,27 and psychological testing. Electrocardiogra-
phy, heart and lung x-ray, and extracranial color Doppler
of carotid and vertebral arteries showed normal findings
in all study patients, hospitalized for the first time at De-
partment of Psychiatry, General Hospital in Slavonski
Brod. Lindergaard’s index in all patients were 1,7±0,4;
regular. Control group consisted of 50 age-matched male
subjects who had not been involved in war actions and
were free from PTSD or any other mental disorder. Dur-
ing the war, these subjects were living in areas not af-
fected by war actions.
On day 1 of hospital admission, the level of VMA in
24-h urine was determined and TCD study of cerebral
circulation was performed. In order to eliminate a poten-
tial laboratory error, patients having taken banana, va-
nilla, chocolate, coffee and alcohol in the past three days
were excluded for the possible effect on 24-h VMA. Labo-
ratory analysis of adrenomedullary hormones was per-
formed by measuring VMA as a catecholamine metabo-
lism end-product in 24-h urine. Diurnal variation in
catecholamine secretion and the impact of daily stressors
that may enhance their production were obviated by 24-h
measurement. The normal range of 24-h urine VMA is
10–35 mmol/dU; the levels exceeding 35 mmol/dU were
considered as elevated. TCD study included MBFV mea-
surement in the circle of Willis vasculature, but values of
MBFV in arteria cerebri media over 120 cm/sec were take
for cerebral vasospasm. The study of cerebral hemody-
namics was performed on an EME Trans-scan 3D device
with a 2 MHz probe, using standardized MBFV values
expressed in centimeters per second (cm/s). Elevated
MBFV with typically extended frequency spectra were
considered to reflect cerebral vasospasm consequential
to prolonged contraction of the cerebral arterial wall
smooth muscle28–30.
These studies were repeated after 3-week hospital
stay and psychiatric treatment with antidepressants and
anxiolytics, and results of the two measurements as well
as those recorded in the control group were compared.
On statistical analysis, the test of proportion between
two groups was employed. The level of statistical signifi-
cance was set at p<0.05. The results thus obtained were
used to assess the association of different subject groups
with elevated levels of catecholamines and changes in ce-
rebral hemodynamics.
Results
The initial measurement of 24-h VMA showed ele-
vated levels in 29 (58%) chronic PTSD patients and none
of the control subjects. The difference was statistically
significant (p=0.0000) (Table 1). On repeat measure-
ment performed after 3-week psychopharmaceutical the-
rapy, elevated 24-h VMA was recorded in ten (20%) pa-
tients. The difference from the initial measurement was
statistically significant (p=0.0000), pointing to a consid-
erably higher rate of elevated VMA in untreated chronic
PTSD patients (Table 2).
In chronic PTSD patients, initial TCD studies were
performed upon hospital admission, before the initiation
of psychiatric therapy. Elevated MBFV in the circle of
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TABLE 1








PTSD patients 29 (58.00%) 21 (42.00%) 50 (100.00%)
Control group 0 (0.00%) 50 (80.00%) 50 (100.00%)
p-proportion test; p=0.0000
TABLE 2











29 (58.00%) 21 (42.00%) 50 (100.00%)
Second
measurement
10 (20.00%) 40 (80.00%) 50 (100.00%)
p-proportion test; p=0.0000
Willis vasculature was recorded in 34 (68%) patients and
two (4%) control subjects, yielding a statistically signifi-
cant difference (p=0.0000) (Table 3). Repeat TCD stud-
ies were obtained after 3-week psychopharmaceutical
therapy and revealed vasospasm in only nine (18%) pa-
tients. The difference between the two measurements in
PTSD patients was statistically significant (p=0.0000),
pointing to a considerably greater rate of vasospasm in
the circle of Willis vasculature in untreated PTSD pa-
tients (Table 4).
Comparison of the subgroups of with the circle of Wil-
lis vasospasm and elevated 24-h VMA on initial measure-
ment showed no statistically significant between-group
difference (p=0.3290), pointing to the association of the
circle of Willis vasospasm and VMA elevation in un-
treated PTSD patients (Table 5).
The same association was studied between subject
subgroups with the circle of Willis vasospasm and ele-
vated 24-h VMA on repeat measurement, yielding no sta-
tistically significant between-group difference either (p=
0.7906) and pointing to the concurrence of the circle of
Willis vasospasm and VMA elevation in PTSD patients
(Table 6).
Discussion
Patients with untreated PTSD were found to have a
considerably higher rate of elevated VMA and the circle
of Willis vasospasm than the control group of healthy
subjects. Although 3-week psychiatric treatment resul-
ted in a significant reduction of these abnormalities in
PTSD patients, they still showed a statistically signifi-
cantly higher rate in comparison with control group.
There was a high correlation between elevated catecho-
lamine levels and cerebral vasospasm on both initial and
repeat measurements.
A number of studies have already demonstrated the
adrenergic system activity to be enhanced by stress. In
spite of the long time that has elapsed since their stress
exposure, PTSD patients develop a pathological response
to stress, which results in elevated baseline catechol-
amine levels31–34. Such a pathological response was con-
firmed in the present study, where elevated baseline
catecholamine levels were recorded in 58% of PTSD pa-
tients. The prevalence of elevated blood pressure and in-
creased pulse rate is statistically significantly greater in
these patients than in their healthy age-matched coun-
terparts35–37. Other studies have also reported elevated
24-h VMA levels in PTSD patients38–41. Our results con-
firmed these reports and pointed to the role of pre- and
post-therapeutic 24-h VMA analysis in untreated chronic
PTSD patients. Therapeutic efficacy could be evaluated
by monitoring VMA pattern in these patients.
Our previous studies have pointed to increased MBFV
in the basal cerebral arteries of patients with chronic
PTSD, with changes in the frequency spectra suggestive
of vasospasm11,12. Results of our study confirmed the
presence of cerebral vasospasm in the majority of PTSD
patients and pointed to the value of TCD study as a diag-
nostic method for the detection and monitoring of hemo-
dynamic events in the cerebral vasculature of patients
with chronic PTSD.
To the best of our knowledge, there are no studies of
the association of elevated VMA levels and cerebral he-
modynamics in chronic PTSD patients. There are re-
ports on functional testing demonstrating relatively ra-
pid changes of cerebral perfusion in some physiologic
conditions. For example, a 38%–66% MBFV increase
from baseline was recorded in intracranial arteries as
early as 3 minutes of the cerebral circulation stimulation
with acetazolamide. The higher degree of carotid steno-
sis correlated with poorer vasoreactivity in the ipsilateral
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34 (68.00%) 16 (32.00%) 50 (100.00%)
Control group 2 (4.00%) 48 (96.00%) 50 (100.00%)
p-proportion test; p=0.0000
TABLE 4








34 (68.00%) 16 (32.00%) 50 (100.00%)
Second measure-
ments of PTSD
9 (18.00%) 41 (82.00%) 50 (100.00%)
p-proportion test; p=0.0000
TABLE 5
CORRELATION BETWEEN CEREBRAL VASOSPASM AND
INCREASED VMA (FIRST MEASUREMENT)
Examines N %
Vasospasm Willis 34 68.00




CORRELATION BETWEEN CEREBRAL VASOSPASM AND
INCREASED VMA (SECOND MEASUREMENT)
Examines N %
Vasospasm Willis 9 18.00 p=0.7906
Increased VMA 8 16.00
Total 50 100.00
p=0.7906
cerebral hemisphere42. Induction of functional brain stress
induced by various cognitive stimuli such as reading,
light, sound, visualization, speech imaging, etc. revealed
MBFV elevation in the brain regions activated by the
particular stimulus. Upon stimulus discontinuation, the
MBFV returned to baseline levels43–45. The most pro-
nounced vasospasm was observed in patients with su-
barachnoid hemorrhage46.Clinical relevance of prolonged
cerebral vasospasm found in patients with chronic PTSD
has not yet been fully clarified. As PTSD patients have a
higher prevalence of various risk factors for atherosclero-
sis, e.g., cigarette smoking, arterial hypertension, alco-
holism, obesity, hyperlipidemia, diabetes mellitus, etc.,
they are quite likely to be at a considerably greater risk
of atherosclerosis, cerebrovascular and cardiovascular
disorders19–22,47. Therefore, it is of utmost importance to
continue research into the association of pathophysio-
logic changes in PTSD and cerebral circulation, and to
monitor the somatic sequels of PTSD at long term. TCD
analysis of cerebral circulation with concurrent evalua-
tion of 24-h VMA can facilitate diagnostic work-up, along
with appropriate monitoring of the course of disease and
psychotherapeutic efficacy.
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UTJECAJ POVI[ENE RAZINE KATEHOLAMINA U BOLESNIKA S KRONI^NIM
POSTTRAUMATSKIM STRESNIM POREME]AJEM NA CEREBRALNU HEMODINAMIKU
S A @ E T A K
Cilj ovog istra`ivanja je utvrditi povezanost izme|u razine kateholamina i promjena cerebralne hemodinamike u
bolesnika s kroni~nim postraumatskim stresnim poreme}ajem (PTSP). Ispitivanjem je obuhva}eno 50 bolesnika s kro-
ni~nim PTSP-em koji su prvi puta hospitalizirani i psihijatrijski lije~eni te 50 zdravih ispitanika kontrolne skupine. Svi
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ispitanici bili su u dobi izme|u 30 i 50 godina. PTSP bolesnicima prvog su dana boravka analizirane vrijednosti vanil-
mandeli~ne kiseline (VMA) i metabolita adrenalina i noradrenalina u 24-satnom urinu te je u~injena analiza krvnih `ila
Willisovog kruga transkranijskom dopler sonografijom (TCD). Isti dijagnosti~ki postupci ponovljeni su nakon 21-dnev-
nog medikamentoznog psihijatrijskog tretmana. Prva analiza pokazala je istovremeno povi{ene razine 24-satne VMA
kod 29 (58,00%) bolesnika i povi{ene vrijednosti srednjih brzina strujanja krvi (SBSK) krvnih `ila Willisova kruga u 34
(68,00%) bolesnika {to ukazuje na visoku podudarnost promatranih parametara (p=0,3290). Druga analiza koja je
u~injena nakon 21-dnevnog psihijatrijskog lije~enja pokazala je istovremeno povi{enu razinu 24-satne VMA u 8 (16,00%)
bolesnika i povi{ene SBSK krvnih `ila Willisova kruga u 9 (18,00%) bolesnika {to ukazuje na visoku podudarnost pro-
matranih parametara (p=0,7906). U kontrolnoj skupini osoba bez PTSP-a svega je 2 (4,00%) ispitanika imalo povi{ene
SBSK krvnih `ila Willisova kruga, dok je razina 24-satne VMA u svih ispitanika bila uredna. Istra`ivanje je pokazalo
zna~ajnu povezanost izme|u povi{ene razine stresnih hormona i povi{enih SBSK u krvnim `ilama Willisovog kruga
koje su uzrokovane cerebralnim vazospazmom. Medikamentozno psihijatrijsko lije~enje PTSP-a u trajanju od tri tjedna
dovelo je do zna~ajnog smanjenja udjela bolesnika s povi{enom razinom metabolita kateholamina i zna~ajnog sma-
njenja cerebralnog vazospazma. Rezultati istra`ivanja su pokazali visok stupanj korelacije izme|u dnevne razine VMA i
povi{enih SBSK u krvnim `ilama Willisovog kruga {to jasno ukazuje da dugotrajno povi{ena razina kateholamina utje-
~e na cerebralnu hemodinamiku.
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